Therapeutic mRNA vaccines targeting human papillomavirus type 16 E7 protein demonstrate significant antitumor efficacy in murine models of HPV-associated tumors

Q: How does OCRA curate its research paper database?

OCRA indexes peer-reviewed papers from PubMed and CrossRef, enriched with MeSH terms, author profiles, and citation metrics. Papers are categorized by cancer type, research method, and clinical relevance.

Q: Can I search papers by MeSH term or author?

Yes. Use the search bar to filter papers by MeSH term, author name, journal, keyword, or cancer type. Each paper includes linked MeSH terms and author profiles for further exploration.

Q: How current is the paper database?

The database is updated regularly through automated ingestion from PubMed and CrossRef. Most papers appear within days of their PubMed indexing date.

doi:10.1016/j.ijpharm.2025.125785

Human papillomavirus (HPV) infection and persistent high-risk HPV (HR-HPV) infection are considered to be the main causative factors in cervical cancer. Consequently, there is an urgent need to develop safe and effective HPV-targeted therapeutic strategies. In this study, we introduced mutations to E7 protein to eliminate its carcinogenic properties and used microfluidic technology to encapsulate mRNA in lipid nanoparticles (LNPs) to develop therapeutic HPV 16 E7 mRNA-LNP vaccine candidate. E7-specific CD8

Therapeutic mRNA vaccines targeting human papillomavirus type 16 E7 protein demonstrate significant antitumor efficacy in murine models of HPV-associated tumors

Links

Journal

Authors

Funding